Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PENGUIN-2: JNJ-73763989 plus nucleos(t)ide analogs and pegylated interferon alpha-2a in chronic hepatitis B
jRCT2061210044Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2022
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of tomligisiran in hepatitis B (HBV), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of participants with ≥2 log10 IU/mL reduction in HBsAg at Week 24 (EOSI). Started Jan 2022; status: completed.
02
Drugs
tomligisiran
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on jRCT2061210044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061210044.